About 10 million people infected with hepatitis C virus in China can be cured, but the diagnosis rate is only 2%


Release time:

2017-08-03

July 28 is the seventh world hepatitis day, this year's theme is "eliminate hepatitis". Speaking of hepatitis, most people think of hepatitis B first. In fact, hepatitis C is also a "king of destruction" that cannot be ignored in the field of hepatitis ". It is understood that there are currently about 10 million people infected with hepatitis C virus in China. Among the liver cancer deaths 360000 each year, the death rate of liver cancer secondary to hepatitis C accounts for 37.48.

It is understood that at present, hepatitis C has a full oral direct antiviral treatment plan. Professor Xu Xiaoyuan, director of the Department of Infectious Diseases, Peking University Medical Center, pointed out: "Hepatitis C can be cured. Oral antiviral drugs can directly hit the 'target target' on hepatitis C virus, effectively inhibit virus replication and fundamentally eliminate the virus."

1/3 of patients do not know that hepatitis C can be cured

There are currently about 10 million people living with HCV in China, and the number of newly reported cases of HCV has increased from 21000 in 2003 (per year) to 230000 in 2016 (per year). But at the same time, the diagnosis rate of hepatitis C in China is only 2%, and less than 25% of people know what hepatitis C is before diagnosis.

The results of the "Survey on the Cognition and Treatment Status of Hepatitis C Patients in China" show that 90% of patients have more or less wrong perceptions of hepatitis C, especially the necessary medical knowledge in treatment, such as important hepatitis C virus monitoring indicators. Even nearly one-third of patients mistakenly believe that hepatitis C virus will spread through drinking water and eating, and about one-third of patients do not know that hepatitis C can be cured.

It is worth noting that the probability of chronic hepatitis C is high, and it is easy to develop into cirrhosis and even liver cancer. According to statistics, the annual death toll of liver cancer in China is about 360000, of which the death rate of liver cancer secondary to hepatitis C accounts for 37.48 per cent, showing a rapid upward trend. "Direct anti-hepatitis C virus drugs can greatly increase the cure rate of hepatitis C, thereby reducing the mortality of cirrhosis and liver cancer caused by hepatitis C infection." Professor Xu Xiaoyuan, director of the Department of Infectious Diseases, Peking University School of Medicine, appealed, "If the goal of'eliminating hepatitis C 'set by the World Health Organization is to be achieved, by 2030, China will need to treat at least 550000 hepatitis C patients every year. Since there is currently no vaccine for hepatitis C, the best prevention for hepatitis C is treatment. Therefore, only by promoting more hepatitis C patients to use innovative hepatitis C drugs and get cured earlier can the spread of hepatitis C virus be controlled most effectively."

There is a new oral regimen for the treatment of hepatitis C.

It is understood that recently a two-drug combination therapy for the treatment of adult genotype 1b chronic hepatitis C (non-cirrhosis or compensated cirrhosis) has officially landed in China. Professor Xu Xiaoyuan pointed out that this all-oral direct antiviral drug treatment plan can directly hit the "target site" on the hepatitis C virus, effectively inhibit virus replication, and fundamentally eliminate the virus. The results of clinical studies show that the scheme is used to treat patients with genotype 1b chronic hepatitis C, with a cure rate of 91% to 99%, and is safe and well tolerated.

Zhuang Hui, a professor at Peking University School of Medicine and an academician of the Chinese Academy of Engineering, said: "This is the first all-oral direct anti-hepatitis C virus drug. Its clinical use will give more Chinese hepatitis C patients hope to be cured, and make it possible to realize the'elimination of hepatitis C' in China. The vision of hepatitis C has practical feasibility." (All-media reporter Li Heng)